RxDoctor Payments Data

Steven Kanarek, MD

Cardiovascular Disease · Hackensack, NJNPI 1851429518

Payments from drug & device makers

$2,082in general payments, 2019–2025

Across 139 payments — averaging $14.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$617
  • Boehringer Ingelheim$150
  • Boston Scientific$139
  • Amgen$138
  • Pfizer$121
  • Merck$107
  • plus $811 from 20 others

What the payments were for

  • Food & beverage$2,082100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,082 in reported general payments places this provider in the 40th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$254,039
Medicare patients
1,540
Services billed
3,662

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban362$448,972
XareltoRivaroxaban82$102,906
EntrestoSacubitril/Valsartan52$78,628
JardianceEmpagliflozin49$62,484
Repatha SureclickEvolocumab25$36,486
Repatha SyringeEvolocumab20$26,871
FarxigaDapagliflozin Propanediol20$26,350
Ezetimibe859$21,979
JanuviaSitagliptin Phosphate12$18,906
Rosuvastatin Calcium1,048$18,710
Valsartan399$13,214
Metoprolol Succinate638$9,647
Atorvastatin Calcium550$6,686
Amlodipine Besylate672$5,113
Diltiazem 24hr Er (Cd)Diltiazem Hcl126$4,712

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$121$448,972362 claims
Johnson & JohnsonXarelto$39$102,90682 claims
NovartisEntresto$617$78,62852 claims
Boehringer IngelheimJardiance$150$62,48449 claims
AstraZenecaFarxiga$64$26,35020 claims
MerckJanuvia$107$18,90612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Hackensack

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →